Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: A metabolic perspective of treatment

Oncotarget

Volumn 6, Issue 2, 2015, Pages 1217-1230

  Ruggieri, Vitalba ^a   Agriesti, Francesca ^a   Scrima, Rosella ^b   Laurenzana, Ilaria ^a   Perrone, Donatella ^b   Tataranni, Tiziana ^a   Mazzoccoli, Carmela ^a   Muzio, Lorenzo Lo ^b   Capitanio, Nazzareno ^b   Piccoli, Claudia ^a,b  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Dichloroacetate; Mitochondria; Oral squamous cell carcinoma; Oxidative metabolism; Reactive oxygen species

Indexed keywords

DICHLOROACETIC ACID; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PYRUVATE DEHYDROGENASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL METABOLISM; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLISM; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUTH SQUAMOUS CELL CARCINOMA; OXIDATIVE PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA CELL LINE; CELL SURVIVAL; DRUG EFFECTS; IMMUNOBLOTTING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUTH TUMOR; OXIDATION REDUCTION REACTION; PATHOLOGY; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DICHLOROACETIC ACID; GLYCOLYSIS; HUMANS; IMMUNOBLOTTING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MOUTH NEOPLASMS; NAD; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; PHOSPHORYLATION; PYRUVATE DEHYDROGENASE (LIPOAMIDE);

EID: 84921820101     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2721     Document Type: Article

References (43)

1. Durr ML, Li D, Wang SJ. Oral cavity squamous cell carcinoma in never smokers: Analysis of clinicopathologic characteristics and survival. Am J Otolaryngol. 2013; 34:388-393.
2. Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J. 2012; 6:126-130.
3. Jithesh PV, Risk JM, Schache AG, Dhanda J, Lane B, Liloglou T, Shaw RJ. The epigenetic landscape of oral squamous cell carcinoma. Br J Cancer. 2013; 108:370-379.
4. Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Reboiras-López MD, Gándara Rey JM, García-García A. Genetic and molecular alterations associated with oral squamous cell cancer. Oncol Rep. 2009; 22:1277-1282.
5. Di Domenico M, Pierantoni GM, Feola A, Esposito F, Laino L, DE Rosa A, Rullo R, Mazzotta M, Martano M, Sanguedolce F, Perillo L, D'Angelo L, Papagerakis S, et al. Prognostic significance of N-Cadherin expression in oral squamous cell carcinoma. Anticancer Res. 2011; 31:4211-4218.
6. Tripathi P, Kamarajan P, Somashekar BS, MacKinnon N, Chinnaiyan AM, Kapila YL, Rajendiran TM, Ramamoorthy A. Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. Int J Biochem Cell Biol. 2012; 44:1852-1861.
7. Kroemer G. cancer's Achilles' heel. Cancer Cell. 2008; 13:472-482.
8. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol. 2012; 23:352-361.
9. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012; 12:685-698.
10. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005; 65:613-621.
11. Chen Y, Cairns R, Papandreou I, Koong A, Denko NC. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One. 2009; 4:e7033.
12. Sánchez-Aragó M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis. 2010; 31:567-576.
13. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat. 2010; 120:253-260.
14. Saed GM, Fletcher NM, Jiang ZL, Abu-Soud HM, Diamond MP. Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress. Reprod Sci. 2011; 18:1253-1261.
15. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol. 2008; 109:394-402.
16. Vella S, Conti M, Tasso R, Cancedda R, Pagano A. Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells. Int J Cancer. 2012; 130:1484-1493.
17. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010; 2:31-34.
18. Kumar A, Kant S, Singh SM. Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation. Chem Biol Interact. 2012; 199:29-37.
19. Sutendra G, Michelakis ED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol. 2013; 3:38.
20. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, Bartenstein P, Wagner W, Whiteside TL. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003; 97:1015-1024.
21. Yoneda K, Yamamoto T, Osaki T. p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation. Oral Oncology. 1998; 34:529-553.
22. Quarato G, Piccoli C, Scrima R, Capitanio N. Variation of flux control coefficient of cytochrome c oxidase and of the other respiratory chain complexes at different values of protonmotive force occurs by a threshold mechanism. Biochim Biophys Acta. 2011; 1807:1114-1124.
23. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008; 283:22700-22708.
24. Campello S, Scorrano L. Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep. 2010; 11:678-684.
25. Sanchez WY, McGee SL, Connor T, Mottram B, Wilkinson A, Whitehead JP, Vuckovic S, Catley L. Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib. Br J Cancer. 2013; 108:1624-1633.
26. Lo Muzio L, Sartini D, Santarelli A, Rocchetti R, Morganti S, Pozzi V, Rubini C, Bambini F, Emanuelli M. Expression and prognostic significance of apoptotic genes in oral squamous cell carcinoma. Mol Carcinog. 2014; 53:264-271.
27. Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell carcinoma. Oncol Lett. 2014; 8:7-11.
28. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013; 4:e532.
29. Wen S, Zhu D, Huang P. Targeting cancer cell mitochondria as a therapeutic approach. Future Med Chem. 2013; 5:53-67.
30. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4:891-899.
31. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007; 274:1393-1418.
32. Jose C, Rossignol R. rationale for mitochondrial targeting strategies in cancer bioenergetic therapies. Int J Biochem Cell Biol. 2013; 45:123-129.
33. Popovic DM. Current advances in research of cytochrome c oxidase. Amino Acids. 2013; 45:1073-1087.
34. Bensaad K. new roles in metabolism. Trends Cell Biol. 2007; 17:286-291.
35. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science. 2006; 312:1650-1653.
36. Jha MK, Suk K. Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas. Brain Tumor Res Treat. 2013; 1:57-63.
37. Agnoletto C, Melloni E, Casciano F, Rigolin GM, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Oncotarget. 2014; 5:4347-4360.
38. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010; 10:267-277.
39. Palmer CS, Osellame LD, Stojanovski D, Ryan MT. The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery. Cell Signal. 2011; 23:1534-1545.
40. Scorrano L. Keeping mitochondria in shape: a matter of life and death. Eur J Clin Invest. 2013; 43:886-893.
41. Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 2013; 20:31-42.
42. Pathak RK, Marrache S, Harn DA, Dhar S. Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate. ACS Chem Biol. 2014; 9:1178-1187.
43. Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-time and label-free monitoring of cell viability. Biochim Biophys Acta. 2011; 1807:1114-1124.